STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations Meeting Abstract
| Authors: | Patel, M. R.; Bauer, T. M.; Liu, S. V.; Drilon, A. E.; Wheler, J. J.; Shaw, A. T.; Farago, A. F.; Ou, S. H. I.; Luo, D.; Yeh, L.; Hornby, Z.; Senderowicz, A. M.; Lim, J. |
| Abstract Title: | STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900629 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.2596 |
| Notes: | Meeting Abstract: 2596 -- Source: Wos |
